Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes.
Allogeneic SCT is the most effective method to achieve cure in patients with MPD and MDS. This approach is associated with significant risk of morbidity (eg, GVHD) and TRM, although the incidence and severity vary based on donor and recipient characteristics. For young patients with HLA-matched donors, SCT is the preferred therapy. Efforts to improve outcome for older patients and for patients with alternative donors have led to decreased treatment-associated complications with associated better long-term DFS.
Wayne
Alan S
AS
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 13N240, 10 Center Drive, MSC-1928, Bethesda, MD 20892-1928, USA. waynea@mail.nih.gov
Barrett
A J
AJ
D006801:Humans; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D009196:Myeloproliferative Disorders / Q000628:therapy*; D033581:Stem Cell Transplantation; D014019:Tissue Donors; D014184:Transplantation, Homologous